Development of novel treatment strategies for inflammatory diseases-similarities and divergence between glucocorticoids and GILZ

Qiang Cheng, Eric Francis Morand, Yuan Hang Yang

Research output: Contribution to journalArticleResearchpeer-review

30 Citations (Scopus)

Abstract

Glucocorticoids (GC) are the most commonly prescribed medications for patients with inflammatory diseases, despite their well-known adverse metabolic effects. Previously, it was understood that the anti-inflammatory effects of the GC/GC receptor (GR) complex were mediated via transrepression, whilst the adverse metabolic effects were mediated via transactivation. It has recently become clear that this divergent actions paradigm of GC actions is likely insufficient. It has been reported that the GC/GR-mediated transactivation also contributes to the anti-inflammatory actions of GC, via up-regulation of key anti-inflammatory proteins. One of these is glucocorticoid-induced leucine zipper (GILZ), which inhibits inflammatory responses in a number of important immune cell lineages in vitro, as well as in animal models of inflammatory diseases in vivo. This review aims to compare the GILZ and GC effects on specific cell lineages and animal models of inflammatory diseases. The fact that the actions of GILZ permit a GILZ-based gene therapy to lack GC-like adverse effects presents the potential for development of new strategies to treat patients with inflammatory diseases.
Original languageEnglish
Pages (from-to)1 - 10
Number of pages10
JournalFrontiers in Pharmacology
Volume5
Issue number(Art. No.: 169)
DOIs
Publication statusPublished - 2014

Cite this